Table 3.
Previous and concurrent DMARD treatments
| JAKi (n = 28) | Rituximab (n = 19) | |
|---|---|---|
| Previous treatments | ||
|
No. of previous csDMARDs median, (IQR) |
3 (2–4) | 3 (2–4) |
|
Methotrexate n, (%) |
22 (78.6%) | 13 (68.4%) |
|
Biologic Naïve n, (%) |
8 (28.6%) | 6 (31.6%) |
|
No. of previous biologics median, (IQR) |
1 (0–2) | 0 (0–1) |
|
Rituximab/JAKi n, (%) |
12 (42.9%) | 1 (5.3%) |
|
TNF-α inhibitor n, (%) |
15 (53.6%) | 5 (26.3%) |
|
Tocilizumab n, (%) |
6 (21.4%) | 1 (5.3%) |
|
Abatacept n, (%) |
6 (21.4%) | 1 (5.3%) |
| Concurrent treatments | ||
| Prednisolone; n, (%) | 13 (46.4%) | 6 (31.6%) |
| Prednisolone dose (mg) median, (IQR) | 7 (5–10) | 10 (4.5–12.5) |
|
Methotrexate n, (%) |
4 (14.3%) | 2 (10.5%) |
|
Azathioprine n, (%) |
2 (7.1%) | 2 (10.5%) |
|
Leflunomide n, (%) |
2 (7.1%) | 2 (10.5%) |
|
Hydroxychloroquine n, (%) |
6 (21.4%) | 6 (31.6%) |
|
Sulfasalazine n, (%) |
3 (10.7%) | 4 (21.1%) |
DMARD disease-modifying anti-rheumatic drugs, csDMARDs conventional synthetic DMARDs, JAKi Janus kinase inhibitor, IQR inter-quartile range, TNF Tumour necrosis factor